BioPharma Dive November 30, 2022
The company, which is partnered with Jim Wilson’s UPenn lab, chose to extend an existing financing round after seeing other biotechs struggle to win more cash.
Philadelphia-based gene editing startup iECURE has raised $65 million in additional Series A venture funding, the company announced Wednesday.
The fresh cash infusion increases iECURE’s total financing to date to $115 million, and will help the startup advance its lead research program into clinical testing, said iECURE CEO Joseph Truitt.
The company’s lead drug candidate, dubbed GTP-506, is designed to treat ornithine transcarbamylase, or OTC, deficiency in infants. The rare inherited disease, which leads to the build-up of ammonia in the blood, does not have a drug specifically approved to treat it, although...
Today's Sponsors
Today's Sponsor